Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics  

作　　者：Shintaro Akiyama Thomas G Cotter Atsushi Sakuraba 

机构地区：[1]Section of Gastroenterology,Hepatology and Nutrition,Department of Medicine,University of Chicago,Chicago,IL 60637,United States

出　　处：《World Journal of Gastroenterology》2021年第19期2312-2324,共13页世界胃肠病学杂志（英文版）

摘　　要：Hepatitis B virus reactivation(HBVr)can occur in patients treated with immunosuppressive medications.Risk stratification for HBVr based on hepatitis B virus(HBV)serology and viral load is an important strategy to determine appropriate HBV monitoring and antiviral prophylaxis use.Recent advances in the understanding of pathophysiology of autoimmune diseases have led the development of cytokine-targeted therapies.Tumor necrosis factor(TNF)-αinhibitors have been widely used for patients with inflammatory bowel disease,psoriasis,and rheumatic diseases.Further,the clinical benefits of interleukin(IL)-12/23,IL-17,or Janus kinases inhibitors have been demonstrated in these patients.It is well known that TNF-αinhibitor use can lead to HBVr,however,the risk of HBVr in patients undergoing non-TNF-targeted biologics have not been fully understood.In this review,we discuss the risk of HBVr in patients treated with non-TNF-targeted biologics,and immunological mechanisms of these medications causing HBVr.

关 键 词：Hepatitis B virus Autoimmune diseases Biological therapy INTERLEUKIN-23 INTERLEUKIN-17 Janus kinases 

分 类 号：R593.2[医药卫生—内科学] R512.62[医药卫生—临床医学]